CA2381926A1 - Marqueurs inflammatoires systemiques en tant qu'outils diagnostiques dans la prevention des maladies atherosclereuses - Google Patents
Marqueurs inflammatoires systemiques en tant qu'outils diagnostiques dans la prevention des maladies atherosclereuses Download PDFInfo
- Publication number
- CA2381926A1 CA2381926A1 CA002381926A CA2381926A CA2381926A1 CA 2381926 A1 CA2381926 A1 CA 2381926A1 CA 002381926 A CA002381926 A CA 002381926A CA 2381926 A CA2381926 A CA 2381926A CA 2381926 A1 CA2381926 A1 CA 2381926A1
- Authority
- CA
- Canada
- Prior art keywords
- agent
- subject
- risk
- sodium
- marker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des procédés servant à caractériser, chez un individu, un profil de risque de développement futur d'une maladie cardio-vasculaire, et consistant à obtenir un niveau du marqueur d'inflammation systémique de cet individu. L'invention concerne également des procédés d'évaluation de la possibilité qu'un traitement, à base d'un agent réduisant le risque de développement futur d'une maladie cardio-vasculaire, va être bénéfique pour un individu.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/387,028 US7030152B1 (en) | 1997-04-02 | 1999-08-31 | Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
US09/387,028 | 1999-08-31 | ||
PCT/US2000/024251 WO2001015744A1 (fr) | 1999-08-31 | 2000-08-31 | Marqueurs inflammatoires systemiques en tant qu'outils diagnostiques dans la prevention des maladies atherosclereuses |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2381926A1 true CA2381926A1 (fr) | 2001-03-08 |
Family
ID=23528141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002381926A Abandoned CA2381926A1 (fr) | 1999-08-31 | 2000-08-31 | Marqueurs inflammatoires systemiques en tant qu'outils diagnostiques dans la prevention des maladies atherosclereuses |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1212101A1 (fr) |
JP (1) | JP2003508453A (fr) |
AU (1) | AU782386C (fr) |
CA (1) | CA2381926A1 (fr) |
WO (1) | WO2001015744A1 (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
US6787532B2 (en) | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
CA2464531A1 (fr) | 2001-11-05 | 2003-05-15 | Brigham And Women's Hospital, Inc. | Cd40l(cd154) soluble en tant que marqueur pour le diagnostic de maladies d'atherosclerose |
AU2003231730A1 (en) * | 2002-05-03 | 2003-11-17 | Alcon, Inc. | Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac |
GB0229747D0 (en) | 2002-12-20 | 2003-01-29 | Axis Shield Asa | Assay |
US20050065184A1 (en) * | 2003-08-29 | 2005-03-24 | Aaipharma Inc. | Method of reducing the risk of oxidative stress |
GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
WO2005110422A2 (fr) | 2004-05-19 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Procede pour traiter des maladies et des etats associes a un niveau modifie de peptides beta amyloides et nouveaux composes d'enolcarboxamide |
JP5728488B2 (ja) | 2009-11-13 | 2015-06-03 | ビージー メディシン, インコーポレイテッド | 心筋梗塞のリスクファクターおよび予測 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69829293T2 (de) * | 1997-04-02 | 2006-04-13 | The Brigham And Women's Hospital Inc., Boston | Verwendung eines mittels zur verminderung des risikos kardiovaskulärer erkrankungen |
AU745797B2 (en) * | 1997-04-18 | 2002-03-28 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders |
-
2000
- 2000-08-31 WO PCT/US2000/024251 patent/WO2001015744A1/fr active IP Right Grant
- 2000-08-31 CA CA002381926A patent/CA2381926A1/fr not_active Abandoned
- 2000-08-31 EP EP00959851A patent/EP1212101A1/fr not_active Withdrawn
- 2000-08-31 JP JP2001520155A patent/JP2003508453A/ja active Pending
- 2000-08-31 AU AU71103/00A patent/AU782386C/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
WO2001015744A9 (fr) | 2002-09-26 |
WO2001015744A1 (fr) | 2001-03-08 |
EP1212101A1 (fr) | 2002-06-12 |
JP2003508453A (ja) | 2003-03-04 |
AU782386B2 (en) | 2005-07-21 |
AU7110300A (en) | 2001-03-26 |
AU782386C (en) | 2006-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7964614B2 (en) | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease | |
US11435363B2 (en) | Relevance of achieved levels of markers of systemic inflammation following treatment | |
US7189518B2 (en) | Soluble CD40L(CD154) as a prognostic marker of atherosclerotic diseases | |
US8846321B2 (en) | Association of levels of HDL-cholesterol apolipoprotein CIII with the risk of coronary heart disease and cardiovascular events | |
US6040147A (en) | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease | |
AU782386C (en) | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases | |
WO2003088811A2 (fr) | Gelsoline utilisee en tant que marqueur pronostique de maladies atherosclereuses | |
EP1520590A1 (fr) | Marquerrs inflammatoires systémiques en tant qu'outils diagnostiques dans la prévention des maladies atherosclereuses | |
EP1767223A1 (fr) | Marqueurs inflammatoires systemiques en tant qu'outils diagnostiques dans la prevention des maladies atherosclereuses | |
AU2005225101A1 (en) | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclered diseases | |
AU2002343620A1 (en) | Soluble CD40L(CD154) as a prognostic marker of atherosclerotic diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |